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ABSTRACT 
 
Immune system dysregulation has been demonstrated to occur during spaceflight and has 
the potential to cause serious health risks to crewmembers participating in exploration-class 
missions.   A comprehensive immune assessment was recently performed on 13 short 
duration Space Shuttle crewmembers and 8 long duration International Space Station (ISS) 
crewmembers.  Statistically significant post-flight phenotype alterations (as compared to pre-
flight baseline) for the Shuttle crewmembers included: granulocytosis, increased percentage 
of B cells, reduced percentage of NK cells, elevated CD4/CD8 ratio, elevated levels of 
memory CD4+ T cells, and a CD8+ T cell shift to a less differentiated state.   For the Shuttle 
crewmembers, T cell function was surprisingly elevated post-flight, among both the CD4+ and 
CD8+ subsets.  This is likely an acute stress response in less-deconditioned crewmembers.  
The percentage of CD4+/IL-2+, CD4+/IFNg+ and CD8+/IFNg+ T cells were all decreased at 
landing.  Culture secreted IFNg production was significantly decreased at landing, whereas 
production of Th2 cytokines was largely unchanged.   It was found that the IFNg:IL-10 ratio 
was obviously declined in the Shuttle crewmembers immediately post-flight. A similar pattern 
of alterations were observed for the long duration ISS crewmembers.   In contrast to Shuttle 
crewmembers, the ISS crewmembers demonstrated a dramatic reduction in T cell function 
immediately post-flight.   This may be related to the effect of acute landing stress in 
conjunction with prolonged deconditioning associated with extended flight.  The reduction in 
IFNg:IL-10 ratio (Th2 shift) was also observed post-flight in the ISS crewmembers to a much 
higher degree.  These data indicate consistent peripheral phenotype changes and altered 
cytokine production profiles occur following space travel of both short and long duration.    
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Background 
 
Dysregulation of the immune system has been shown to be associated with spaceflight, and 
there have been several excellent reviews published recently regarding this subject [1,32, 33, 
37].   Specific immune system alterations that have been observed following spaceflight 
(immediate postflight testing) include altered: cytokine production patterns [3, 8, 12, 13, 18, 
23, 31, 34, 35, 36]; NK cell function [2, 17, 22]; leukocyte distribution [8, 39]; monocyte 
function [16, 20]; neutrophil function [15, 39]; T cell intracellular signaling [5, 6, 19, 27, 28]; 
neuorendocrine responses [40]; leukocyte proliferation following activation [14, 24].   Due to 
the complexities associated with in-flight experiments, there have been comparatively few in-
flight studies of immune function.  Those that have been performed have found reactivation of 
latent herpes viruses during short duration flight [21, 25, 26, 38] and altered cell mediated 
immunity during long duration flight (4, 11).   As a whole, these data strongly suggest that 
immune dysregulation is associated with spaceflight, regardless of duration.  However, the 
precise in-flight nature of the dysregulation, especially as equilibrates over longer duration 
flights (distinct from launch/landing stresses) is not known.   
 
The goal of NASA and the space life science community is to determine the clinical risks 
associated with all flight effects on human physiology, so that countermeasures may be 
developed prior to the initiation of exploration-class space missions.  This need has been 
heightened by the impending lunar/Mars program, which are scheduled be initiated by NASA 
in the next decade.   
 
The data presented in this article outline the results of a comprehensive assessment of 
immunity, consisting of peripheral immune phenotype, cytokine production profiles 
(intracellular and secreted), as well as T cell function.  This study was performed pre- and 
post-flight on both short-duration (Shuttle) and long-duration International Space Station (ISS) 
crewmembers as part of the Epstein Barr flight study (E129, DSO-500).  Epstein Barr 
assesses immunity, physiological stress and latent viral reactivation following spaceflight.  
NASA will follow this post-flight study with a related in-flight study (Integrated Immue, SMO-
015, SDBI-1900) that will commence in late 2007.   Integrated Immune will distinguish what 
immune dysregulation persists during flight from post-flight assessments that have the 
potential to be influenced by landing and readaptation. 
 
 
 
Materials and Methods 
 
Subjects/missions.  13 short duration Space Shuttle crewmembers and 8 long duration ISS 
crewmembers participated in this study.  The Shuttle astronauts flew on Space Shuttle 
missions STS-114, STS-121, STS-115 and STS-116.  The ISS astronauts (or Russian 
cosmonauts) flew on ISS Expeditions 11, 12, 13 and 14.  Institutional review board approval 
was obtained from the Committee for the Protection of Human Subjects at the Johnson 
Space Center; Houston, TX.  Informed consent was obtained from all subjects who 
participated in the study.    
 
Whole blood samples.  For this study the sample consisted of 1.0 ml heparin or 0.5 ml 
EDTA anticoagulated whole blood.   Whole blood samples were collected by standard 
phlebotomy techniques according to the schedule shown in figure 1.   ‘L-_‘ indicates the 
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number of days prior to launch a sample was collected and ‘R+_’ indicates the number of 
days following landing a sample is collected.  The precise date of sampling could vary due to 
crew training schedules and other logistical considerations (especially true for ISS 
crewmembers), and not every sample was collected on each subject.  However, for all 
subjects a landing day (R+0) sample was collected, in addition to at least two pre-mission 
baseline samples and a post-mission recovery timepoint.  For immediate post-flight samples 
processed remotely at either the Kennedy Space Center (Shuttle landing) or Star City, Russia 
(Soyuz landing), cells or culture supernatants were stained and stabilized as previously 
described (7) and transported to JSC for analysis. 
 
Immunophenotype analysis.  A comprehensive 5-color flow cytometry antibody matrix was 
created that assessed all the major leukocyte/lymphocyte subsets, as well as various 
activated, cytotoxic/effector and memory/naïve T cell subsets.   Cell surface markers were 
stained first diluting the 500ul whole EDTA whole blood sample with 500 ul of PBS. One 
hundred microliters of the diluted EDTA whole blood was then combined with 10 μl of each 
appropriate labeled monoclonal antibodies.   Staining was performed by incubating the 
mixture at room temperature for a minimum of 20 minutes.   Red blood cells were then lysed 
using the Beckman-Coulter Optilyse reagent as described by the manufacturer, and the cells 
were washed in PBS.  The stained leukocytes were then fixed in 1.0% paraformaldehyde in 
PBS for 10 minutes and analyzed on a Beckman-Coulter Epics XL flow cytometer.  The 
cytometry panel is outlined in table 1.    
 
T cell function.   Immune suppression may consist of a reduced capacity for lymphocytes to 
respond to stimulus, even though the relative distribution of immune cells is unchanged.  For 
this study the functional response of T cells was measured by activating whole blood cultures 
in the presence of T cell mitogenic stimuli, followed by measurement of surface activation 
marker expression on T cell subsets.  Culture in the presence of anti-CD3 and anti-CD28 
antibodies was used for T cell stimulation.  These antibodies activate T cells by triggering T 
cell surface molecules, requiring the full compliment of intracellular signaling to be utilized (as 
opposed to phorbol ester or ionomycin).  T cell progression through a full activation cycle may 
be monitored by culturing cells after 24 hours by determining the expression of CD69 (early 
activation) and CD25 (mid-activation, receptor for IL-2 that requires new gene synthesis).  It 
is noteworthy that some individuals are incompatible with T cell activation via soluble 
CD3/CD28 triggering for reasons that are unclear (29, 30).   For this study 8 of 13 Shuttle and 
6 of 8 ISS astronauts were ‘responders’ and compatible with the T cell function assessment.    
Only data from ‘responders’ are presented.    
 
 
Intracellular cytokine analysis.   Lymphocyte and monocyte cytokine production will be 
assessed for specific cell subsets at the single-cell level utilizing intracellular flow cytometry.  
The unique advantage of intracellular flow cytometry is the ability to assess the production of 
multiple cytokines simultaneously in positively identified cell sub-populations using multi-color 
flow cytometry.   Whole blood cultures will be set up by adding 100 ul heparin whole blood to 
1.0 culture media containing 10 ng/ml PMA, 1.0 ug/ml ionomycin and 3 uM monensin.  
Cultures were incubated for 4.0 hours at 37 degrees C.   Following incubation, the 
supernatants were removed, the RBCs lysed as noted above, and the remaining WBCs were 
fixed in 4.0% paraformaldehyde for 10 minutes.   To detect intracellular production of IFNγ or 
IL-2 (following surface marker staining), the fixed PBMC's were resuspended in 200 μl of 
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permeabilization buffer, consisting of 5.0% non-fat dry milk and 0.5% saponin in PBS to 
which 0.5 μg of labeled mouse antibody to either IFNγ or IL-2 (or both) was added.   The cells 
were incubated at room temperature for 25 minutes and then washed in PBS containing 
saponin.  The cells were then resuspended in 1.0% paraformaldehyde for analysis.    
 
Cytometric Bead Array Analysis.  For analysis of secreted Th1/Th2 cytokine profiles, whole 
blood cultures were set up as described above.  Mitogenic stimulation consisted of either 
anti-CD3/CD28 or PMA+ionomycin for 48 hours.  Following culture, supernatants were 
removed and frozen until analysis.  The Th1/Th2 cytometric bead array assessment was 
performed according to the manufacturer’s instructions (Becton Dickinson).    Since all 
crewmember assessments were batch-analyzed, data are presented as mean fluorescence 
intensity (MFI) to show relative cytokine changes throughout the duration of the mission.   
The MFI directly relates to supernatant cytokine concentration. 
 
Statistical Analysis.   Statistical significance was determined using the Student’s Paired T 
Test.   Unless otherwise indicated, statistical significance was determined by comparing the 
mean value for last pre-mission timepoint to R+0 landing day sample.  In the event a 
particular subject missed the last pre-mission timepoint, the missing data was imputed from 
the other baseline timepoint,so that in all cases R+0 data were compared to pre-flight 
baseline values.  The differences between timepoints were considered significant if P < 0.05 
and are indicated as such (*) on each data figure. 
 
 
Results 
 
Immunophenotype.   Alterations were observed in the distribution of the peripheral 
leukocyte subsets immediately following landing for both the Shuttle crewmembers and the 
ISS crewmembers.  To assess significance, landing day data was compared to pre-flight 
baseline data (usually the L-10 values).   Data are presented in tables 2 and 3 for both 
Shuttle and ISS crewmembers, respectively.   
 
For the Shuttle crewmembers, statistically significant subset changes upon landing (as 
compared to pre-flight baseline values) included granulocytosis, decreased lymphocyte 
percentage, elevated B cells and decreased NK cells.   The percentage of ‘bulk’ memory 
CD4+ /CD45RO+ T cells was significantly elevated after flight, but the level of ‘bulk’ memory 
CD8+/CD45RO+ T cells was unchanged.  Regarding the ‘fine’ memory CD8+ T cell subsets, 
there was a significant shift observed from the late senescent CD28-/CD244+ subset to the 
non-differentiated CD28+/CD244- subset.  There was also a significant reduction in the 
percentage of circulating early senescent CD8+/CD57+ T cells.  Central memory CD8+ T cell 
subsets were assessed, and a significant shift from the terminally differentiated CD62L-
/CD45RA+ subset to the true naïve CD62L+/CD45RA+ subset was observed.   All of these 
analyses indicate the phenotype of the peripheral CD8+ T cells was significantly less 
differentiated (more naïve) following the short-duration space flight.   There were no observed 
increases after landing in any of the early activated (CD69+) or late activated (HLA-DR+) 
CD4+ or CD8+ T cell subsets. 
 
The ISS crewmembers shared some, but not all of the observed post-flight peripheral 
phenotype changes with the Shuttle crewmembers.  For the long duration ISS crewmembers, 
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statistically significant changes upon landing included granulocytosis, decreased lymphocyte 
percentage, elevated B cells and decreased NK cells.   The CD4:CD8 ration was unchanged, 
however there was an elevation in both the CD4 and the CD8 ‘bulk’ memory T cell subsets 
(CD45RO+).   No significant changes were observed in the ISS crewmembers regarding 
central memory, cytotoxic/senescent and activated T cell subsets.    
 
T cell function.   The functional capabilities of the circulating T cell subsets were assessed 
by performing whole blood cultures for 24 hours in the presence of antibodies to CD3 and 
CD28.  Following culture, expression of the early activation surface marker CD69 and later 
activation marker CD25 on T cell subsets were then assessed by multiparameter flow 
cytometry.   Representative flow cytometry scatter plots from one long-duration ISS 
crewmember demonstrating resolution of the activated CD4+ T cell subsets is presented in 
figure 2.   For short duration Space Shuttle crewmembers the mean percentage of both T 
cell subsets that could be stimulated to co-express both activation markers was consistent 
throughout all pre-flight assessments (L-180, L-65, L-10; figure 3A).  Following landing day 
(R+0) assessments, a significant increase in the percentage of T cell subsets that could be 
activated to co-express CD69/CD25 was observed, that resolved to baseline levels by R+14 
(figure 3A).    
 
For ISS crewmembers, the mean percentage of both T cell subsets that could be stimulated 
to full activation (CD69+/CD25+) was also stable between both pre-flight timepoints (figure 
3B).  However, landing day assessments for the ISS crewmembers revealed a significant 
decrease in percentage of both CD4+ and CD8+ T cells that could be stimulated to co-
express CD69/CD25 (figure 3B).  It is noteworthy that the total percentage of T cell subsets 
expressing CD69 alone was reduced, but not significantly different, on landing day.   Thus, 
expression of the early activation marker is relatively unchanged, but the expression of CD25 
(requiring new mRNA expression) was significantly decreased.  Values for the ISS 
crewmembers for this assay trended to resolution at R+3 and had fully returned to baseline 
values by R+30 (figure 3B). 
 
 
Intracellular cytokine analysis.   The percentage of T cell subsets (CD4 and CD8) capable 
of being stimulated to produce either IL-2 or IFNg were determined by intracellular flow 
cytometry following whole blood culture for 5 hours in the presence of PMA, ionomycin and 
monensin (figure 4A, 4B).   For the short duration Shuttle crewmembers, there was a 
significant decrease in the percentage of CD4+/IL-2+ T cells at R+0 as compared to the pre-
mission baseline values (figure 4C).  The percentage of CD8+/IL-2+ T cells was reduced on 
landing day, but not in a significant fashion.  In addition, there was an observable trend 
towards a decrease in both the CD8+/IFNg+ and CD4+/IFNg+ T cell subsets that also did not 
reach significance (figure 4C).   All the observed R+0 intracellular cytokine alterations 
appeared to fully resolve by the R+14 timepoint. 
 
For ISS crewmembers, there a significant decrease in the percentage of CD4+/IL-2+ T cells 
at R+0 as compared to the pre-mission baseline values (figure 4D).  Similarly to the Shuttle 
crewmembers, there was also no significant decrease in the percentage of CD8+/IL-2+, 
CD4+/IFNg+ or CD8+/IFNg+.  In contrast to the Shuttle crewmembers however, we observed 
no trend towards a decrease in the ISS subject for these subsets (figure 4D).  Due to the low 
‘n’, these data were especially vulnerable to masking individual subject variations.   In 
particular, when individual ISS crewmembers data were analyzed, two of the individual long 
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duration crewmembers demonstrated a dramatic reduction in CD8+/IFNg+ subset (data not 
shown).  No other noteworthy individual data were observed. 
 
Secreted Th1/Th2 cytokine analysis.   In an effort to gauge the crewmembers Th1/Th2 
cytokine bias, cytokines secreted during whole blood culture activated with either anti-
CD3/CD28 or PMA+ionomycin were detected by cytometric bead array.  A representative 
flow cytometry scatter plot demonstrating this analysis technique is presented in figure 5A.  
Cytokine expression data are generated as mean fluorescence intensity, and since six 
cytokines are assayed simultaneously, relative comparisons may be made between the 
cytokines.   Also, since all samples were frozen and assayed simultaneously per mission, 
relative comparisons (per crewmember) across the data points are valid.  Figures 5B and 5C 
show average expression for all six cytokines following whole blood CD3/CD28 stimulation 
for Shuttle and ISS crewmembers respectively.  For the shuttle crewmembers, expression of 
IFNg far surpassed all other cytokines, yet there was a statistically significant drop in IFNg 
expression on R+0 that trended to resolve by R+14 (figure 5B).  Interestingly, relative 
expression of IFNg was lower pre-flight for the ISS crewmembers, but also did drop on 
landing day whereas other cytokines appeared unchanged (figure 5C).  Post-flight recovery 
data for the ISS crewmembers revealed IFNg expression that approached the Shuttle 
crewmembers in intensity (figure 5C).  Interestingly, expression of IL-10 among the ISS 
crewmembers was actually elevated at R+0, and trended downwards to baseline values by 
R+30 (Figure 5C).   
 
Average expression for all six cytokines following whole blood PMA and ionomycin 
stimulation are presented for Shuttle and ISS crewmembers in figures 5D and 5E 
respectively.    A differing pattern of expression was obtained following PMA+ionomycin 
stimulation as compared to CD3/CD28 stimulation.  Extremely high levels of IL-2 and IFNg 
predominated, with levels of all four other cytokines minimal by comparison.  This is 
supported by the fact that following PMA+ionomycin stimulation, only IFNg and IL-2 are 
readily detectable by intracellular cytokine assays.   For the Shuttle crewmembers, the 
greatest elevation of IFNg and IL-2 expression was seen at the L-10 and R+3 data points 
(figure 5D).  No other consistent pattern of altered production was observed in the Shuttle 
crewmembers.   For the ISS crewmembers, levels of IFNg and IL-2 expression were also 
highest at R+3.   Interestingly, levels of TNFa, which were minimal at all pre-flight points for 
the ISS crewmembers, was also significantly elevated at R+3 (figure 5E).  These elevations 
were generally trending to resolve by R+30.  Given that an IFNg:IL-10 ratio may be an 
indicator of Th1:Th2 balance, such a ratio was calculated using the CD3/CD28 culture data 
for all crewmembers.  Individual subject IFNg:IL-10 ratios are presented for Shuttle and ISS 
subjects in figures 5F and 5G respectively.   For most Shuttle crewmembers, a relatively 
depressed ration is observed at R+0, as compared to both pre-flight baseline values and 
post-flight recovery data (figure 5F).   For 4 of 5 ISS crewmembers tested, a similar shift was 
detected, but to an even more dramatic level: R+0 IFNg:IL-10 rations were dramatically 
reduced compared to both pre-flight and post-flight recovery data (figure 5G).   To check for 
inter subject and assay variability, four healthy control subjects were evaluated and relatively 
similar timepoints.   The individual control subject data re presented in figure 5H, and show 
that IFNg:IL-10 rations were relatively stable over time, with no Th1:Th2 shifts observed.   
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Discussion 
 
Determining the effect of space travel on the human immune system has proven to be 
extremely challenging.  Limited opportunities for flight studies, varying mission durations, 
technical and logistical obstacles, low subject numbers and a broad range of potential assays 
have contributed to this problem.   Also, the inherent complexity of the immune system, with 
the vast array of cell populations, sub-populations, diverse regulatory molecules and broad 
interactions with other physiological systems makes determining just what to measure 
extremely complicated.  In addition, the perspective of the flight surgeon must be considered 
in determining the clinical significance of immune alterations (relating to a real in-flight clinical 
risk).   The effect of this problem may be observed by scanning publications dealing with 
immunity and space flight, which initiated during the 1970s.    Although an admirable body of 
work, the literature to date suffers from widely varying sampling methods, assay techniques, 
low subject counts and disparate focus on narrow aspects of immunity.  This emphasizes the 
need for an integrated comprehensive approach to determining the effect of immunity during 
space flight.   
 
This study attempted to survey crewmember immune status following spaceflight of both 
short and long duration.  An attempt was made to utilized assays that would have the must 
value in determining clinical risk.  This is difficult since in the sense of broad utility, limited 
phenotyping and viral antibody titers are the only immunology assays used in clinical 
medicine.   For this study a comprehensive phenotype analysis, T cell function and cytokine 
profiles were selected.   It was believed that the phenotype assessment would provide direct 
evidence for in-vivo immune activation/pathology, whereas the functional assessments would 
determine immunity as relates to SAID(spell out and define-looks like done below)  and 
deconditioning.   The granulocytosis observed at landing is almost certainly a transient 
response to the stress of landing, and does not reflect persistent immune alterations.   It is 
possible that at least some of the other phenotypic changes (reduced NK cells, increased 
memory T cells, increased levels of immature CD8+ T cells) are not related to landing effects.  
Of these, the significant reduction in NK cell percentages may represent a risk.  NK cells are 
responsible for tumor surveillance, which would be especially important in the high-energy 
radiation environment of deep space.   
 
T cell function was assessed using CD3/CD28 antibody stimulation and whole blood culture.  
This assay was developed to provide as close as possible a simulation of in-vivo functional 
capabilities.  Whole blood culture retains all soluble plasma factors and does not artificially 
purify cells, retaining any cell-cell interactions that may be required.   Also, CD3/CD28 
activation triggers via the TCR, requiring the full compliment of intracellular signaling to be 
utilized.  A marked reduction in T cell function was observed on landing day for the ISS 
crewmembers (figure 3B), whereas landing day T cell function was actually increased in the 
Shuttle crewmembers (figure 3A).  This dysregulation was observed for both the CD4+ and 
CD8+ T cell subsets.   It is not unexpected that the acute landing-day stress would be 
immunostimulatory in the less-deconditioned Shuttle crewmembers.  Dhabhar et al. have 
shown that acute stress may enhance immunity, whereas chronic stress may be 
immunosuppressive (9, 10).  For the ISS crewmembers it is likely that the longer flight 
duration and more severe deconditioning contributed to the reduction in T cell function.  
Whether the altered function was already present during flight, or was caused by solely 
landing cannot be determined.   Persistently reduced T cell function would almost certainly 
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pose a risk during flight, but even if this is a landing-day only effect it could pose a clinical risk 
for crewmembers landing on Mars.   The initial days on Mars could bring exposure to a 
variety of unique immunological challenges. 
 
Alterations in cytokine production were observed both at the intracellular (reduced numbers 
of cells producing) and the secreted (bulk production, irrespective of source) levels.  The 
reduction in the numbers of T cells capable of being secreted to produce IL-2 were significant 
for both the Shuttle and the ISS crewmembers (figure 4).  The number of T cells capable of 
being secreted to produce IFNg were also reduced, but did not achieve statistical 
significance.   In general reduced cytokine production, as compared to baseline, may be 
considered as a reduction in immune function.  To assess the specific Th1:Th2 balance, the 
secreted cytokine bead array was used.  This assay allows the direct comparison of the 
secretion of multiple cytokines via simultaneous assessment (figure 5A).  For this assay, 
direct comparison of the mean fluorescence intensity (relates to expression level) was utilized 
for data interpretation.   For mean expression among Shuttle crewmembers, following 
CD3/CD28 stimulation there was an obvious mission-associated reduction in IFNg secretion 
that quickly resolved (figure 5B).  Levels of the other cytokines were minimally reduced.  
Interestingly, among the ISS crewmembers a similar reduction if IFNg secretion was 
observed, although with lower baseline values (figure 5C).   It cannot be determined, 
however this may related to prolonged overseas training which the Shuttle crewmembers do 
not experience.   However, levels of IL-10 production in the ISS crewmembers were actually 
elevated postflight (figure 5C).  Reduced IFNg production and elevated IL-10 production 
almost certainly indicates a Th1:Th2 shift has occurred.  As a positive control, culture 
activation was also performed with the pharmacologic agents PMA and ionomycin.  This 
activation is known to produce exceedingly elevated levels of cytokine production.   For the 
Shuttle and ISS crewmembers, mean production of individual cytokines following PMA and 
ionomycin are presented in figures 5D and 5E respectively.  In general, PMA+ionomycin 
stimulation resulted in extremely high levels of IFNg and IL-2 production, yet surprisingly 
minimal levels of the other four cytokines (actually below CD3/CD28 in some cases).  This 
likely explains why PMA+ionomycin are excellent for intracellular IFNg and IL-2, yet poor for 
detection of any other cytokine via that method.   For both Shuttle and ISS, although R+0 
levels were lower compared to post-flight recovery points, it could not be said that mission 
associated changes occurred due to the lower pre-flight baseline values (figures 5D and 
5E).   It is noteworthy that following PMA+ionomycin stimulation, for the ISS crewmembers 
levels of TNFa were elevated at R+0, and much more elevated at R+3, with values resolved 
by R+30 (figure 5E).  Since this change was not observed in the Shuttle crewmembers, this 
must also be related to longer flight duration, and (since levels were higher at R+3) may 
represent readaptation stress following severe deconditioning.   
 
To better illustrate the Th1:Th2 shift in subjects, individual crewmember IFNg:IL-10 ratios 
were plotted for both Shuttle and ISS (figures 5F and 5G respectively).  Although individual 
Shuttle crewmembers varied, in general most demonstrated a Th2 shift at landing that 
resolved postflight (figure 5F).   Among the ISS crewmembers, 4 of 5 demonstrated a 
dramatic Th2 shift, with much higher IL-10 levels (compared to IFNg levels) on R+0 (figure 
5G).  One outlier ISS subject did not follow this trend.   If this Th2 shift persisted during long-
duration flight, and was not a landing day effect, it could represent a significant exploration 
clinical risk for Th2 autoimmune diseases and inflammatory infections.  Data derived from 4 
healthy controls over a similar time span demonstrated that such Th2 shifts are not caused 
 9
by normal subject variation.  All four control subjects had positive ratios with little fluctuation 
over the mission duration (figure 5H).   
 
[Th2 shift more susceptible to viral reactivation, relates to in-flight reactivation 
data?]Spaceflight-associated immune dysfunction (SAID) may be caused by factors uniquely 
associated with space travel (microgravity, radiation) or mission-associated factors not 
uniquely associated with space travel (prolonged confinement, isolation, physiologic stress, 
altered nutrition, altered circadian rhythms or an altered microbial environment).   In fact, it is 
likely that several of these factors synergize during longer flight, resulting in a final common 
(unknown) effect on human immunity.  Although immune dysfunction has been observed 
during even short duration missions, it is not believed that there is a clinical risk associated 
with transient shorter-duration SAID.   In fact, any dysregulation observed during short 
duration flights would be different than the dysfunction that would persist during longer 
duration flight.  The nature of short and long duration flight is dramatically different with 
respect to human physiology.   Shorter flights (primarily Shuttle) are associated with less 
deconditioning and much busier work schedules, whereas longer duration flights (ISS, ~6 
months in duration) are associated with greater deconditioning and prolonged exposure to 
microgravity and radiation.   
 
The data presented here indicate that several interesting immune changes are detectable 
immediately following space flight, including dramatic reductions in T cell function and a Th2 
shift following long-duration flight.  It cannot yet be determined if there is a clinical risk 
associated with immune dysregulation for exploration-class (lunar and Mars) space missions.   
The situation experienced by a crewmember during exploration-class flight will be 
dramatically different from short or long duration orbital flight.   This is primarily due to a lack 
of return option, years of microgravity exposure and deconditioning, significantly higher 
isolation and exposure to higher energy radiation than orbital flight.    A subsequent 
integrated study with in-flight sampling is required to accurately determine the status of the 
immune system during long duration spaceflight and correctly assess the clinical risk for 
exploration-class space missions. 
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FIGURE LEGENDS 
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Marker combination used to identify cell subset
Granulocytes CD45+ CD14- (identified by scatter)
Lymphocytes CD45+ CD14- (identified by scatter)
Monocytes CD45+ CD14+ (identified by scatter)
T cells CD45+ CD3+
B cells CD45+ CD19+
NK cells CD45+ CD16/56+
CD4+ T cells CD3+ CD4+
CD8+ T cells CD3+ CD8+
CD8+ Non-differentiated CD3+ CD8+ CD28+ CD244-
CD8+ Active cytotoxic CD3+ CD8+ CD28+ CD244+
CD8+ late senescent CD3+ CD8+ CD28- CD244+
CD8+ early senescent CD3+ CD8+ CD57+
CD4+ Bulk memory CD3+ CD4+ CD45RA- CD45RO+
CD8+ Bulk memory CD3+ CD8+ CD45RA- CD45RO+
CD8+ True naïve CD3+ CD8+ CD62L+ CD45RA+
CD8+ Central memory CD3+ CD8+ CD62L+ CD45RA-
CD8+ Effector memory CD3+ CD8+ CD62L- CD45RA-
CD8+ Teminally differentiated CD3+ CD8+ CD62L- CD45RA+
T cells, CD4+early activated CD3+ CD4+ CD69+
T cells, CD4+ late activated CD3+ CD4+ HLA-DR+
T cells, CD8+ early activated CD3+ CD8+ CD69+
T cells, CD8+ late activated CD3+ CD8+ HLA-DR+
Table 1:  Phenotype of peripheral leukocyte subsets identified for Shuttle and ISS 
astronauts by multi-color cytometry.
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Timepoint
L-180 L-65 L-10 R+0 R+14
Granulocytes 56 51 56 76* 53
Lymphocytes 36 41 36 17* 39
Monocytes 7 8 7 5 7
T cells 70 69 72 74 71
B cells 11 11 11 16* 11
NK cells 11 12 9 3* 10
CD4+ T cells 63 63 65 70 65
CD8+ T cells 31 32 29 26 30
CD4+ Bulk memory 59 59 58 63* 58
CD8+ Bulk memory 47 43 48 46 46
CD8+ True naïve 38 42 38 44* 37
CD8+ Central memory 14 11 15 16 16
CD8+ Effector memory 27 22 29 27 31
CD8+ Teminally differentiated 21 25 17 13* 17
CD8+ Non-differentiated 41 40 47 56* 45
CD8+ Active cytotoxic 20 15 21 20 19
CD8+ late senescent 28 35 24 16* 27
CD8+ early senescent 9 13 12 5* 11
T cells, CD4+early activated 1 2 1 1 2
T cells, CD4+ late activated 6 7 6 8 6
T cells, CD8+ early activated 4 4 4 3 3
T cells, CD8+ late activated 12 14 12 12 12
*=statistically significant difference from pre-mission values (p,0.05)
Table 2:  Short duration Shuttle astronauts (n=13), mean peripheral phenotype data 
expressed in relative percentages. 
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Timepoint
L-180 L-65 R+0 R+3 R+30
Granulocytes 56 56 71* 53 57
Lymphocytes 36 35 20* 36 34
Monocytes 7 7 8 8 8
T cells 70 70 66 73 71
B cells 10 9 14* 11 9
NK cells 13 12 8* 7 11
CD4+ T cells 61 67 63 67 65
CD8+ T cells 32 27 29 27 28
CD4+ Bulk memory 67 64 73* 63 66
CD8+ Bulk memory 51 48 56* 50 50
CD8+ True naïve 34 37 30 43 35
CD8+ Central memory 33 25 25 18 22
CD8+ Effector memory 23 24 30 26 22
CD8+ Teminally differentiated 10 14 15 13 20
CD8+ Non-differentiated 51 54 49 54 44
CD8+ Active cytotoxic 13 17 20 15 18
CD8+ late senescent 24 24 27 27 38
CD8+ early senescent 10 11 8 6 11
T cells, CD4+early activated 1 1 1 1 1
T cells, CD4+ late activated 8 2 2 4 8
T cells, CD8+ early activated 2 2 2 2 2
T cells, CD8+ late activated 9 8 8 7 12
*=statistically significant difference from pre-mission values (p<0.05)
Ta
a 
 ble 3:  Mean peripheral leukocyte subset data expressed in relative percent, long duration ISS 
stronauts (n=8), 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 16
 
 
 
 
 
 
Figure 1:  Blood collection timepoints for Shuttle and ISS crewmembers.
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FIGURE 2 
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FIGURE 3 
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INTRACELLULAR CYTOKINES:  SHUTTLE
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FIGURE 4 
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FIGURE 5 
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